Last reviewed · How we verify
R-CEOP90
R-CEOP90 is a chemotherapy regimen combining rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, designed to target B-cell malignancies through immunochemotherapy.
R-CEOP90 is a chemotherapy regimen combining rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, designed to target B-cell malignancies through immunochemotherapy. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | R-CEOP90 |
|---|---|
| Sponsor | Fujian Medical University |
| Drug class | Monoclonal antibody + chemotherapy combination |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This combination regimen uses rituximab, a CD20-targeting monoclonal antibody, to selectively eliminate B cells, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) to provide additional cytotoxic activity. The rituximab component enhances antibody-dependent cellular cytotoxicity and direct apoptosis of CD20-positive cells, while the chemotherapy agents work through multiple mechanisms including DNA alkylation and topoisomerase inhibition.
Approved indications
- B-cell non-Hodgkin lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Infection
- Nausea and vomiting
- Alopecia
- Infusion reactions
Key clinical trials
- R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL (PHASE3)
- R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B (PHASE3)
- R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R-CEOP90 CI brief — competitive landscape report
- R-CEOP90 updates RSS · CI watch RSS
- Fujian Medical University portfolio CI